HALO
$28.56
Halozyme Therapeutic
$.36
1.28%
HALO
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  $0.22
Revenue:  N/A
Monday
Nov 9
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Guidance announcement made Monday, August 10, 2020

What do you expect when HALO reports earnings?
Beat
Meet
Miss

Where is HALO's stock price going from here?
Up
Flat
Down
Stock chart of HALO
Analysts
Summary of analysts' recommendations for HALO
Score
Grade
Pivots
Resistance
$30.20
$29.51
$29.04

$28.35

Support
$27.88
$27.19
$26.72
Tweet
Growth
Description
Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.
Peers
BiogenAmgenGilead SciencesNeurocrine BiosciencesSeattle GeneticsBluebird BioQiagen N.V.RepligenNovavaxBio-Techne